SCHEMBL77248

SCHEMBL77248

Cc1nn(C)c(C)c1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24046856 0.89 KDM4E (0.35)
Formamide SCHEMBL20593118 0.85 KDM4E (0.41)
SCHEMBL1559796 0.71
SCHEMBL1632255 0.71
SCHEMBL30615 0.71
SCHEMBL19504920 0.71
SCHEMBL1196791 0.71
SCHEMBL21796085 0.71
SCHEMBL676815 0.71
SCHEMBL4511469 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 716 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021147939-A1 HERBICIDE-RESISTANT POLYPEPTIDE, NUCLEIC ACID AND USE THEREOF 山东舜丰生物科技有限公司 2021-07-29 WO claimed
EP-3527559-A1 GAMMA-BUTYROLACTONE COMPOSITION AND METHOD FOR PRODUCING SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2019-08-21 EP claimed
EP-2164833-B1 Quinazolinamide derivatives useful for the treatment of tumour diseases MERCK PATENT GMBH (DE) 2015-04-15 EP claimed
US-8501754-B2 Quinazolinamide derivatives MERCK PATENT GMBH (DE) 2013-08-06 US claimed
US-7960380-B2 Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators ASTRAZENECA AB (SE) 2011-06-14 US claimed
US-20100234324-A1 Quinazolinamide derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-16 US claimed
US-20100227847-A1 Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators ASTRAZENECA AB (SE) 2010-09-09 US claimed
US-7723333-B2 Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators ASTRAZENECA AB (SE) 2010-05-25 US claimed
US-20090005353-A1 Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators ASTRAZENECA AB (SE) 2009-01-01 US claimed
EP-1838687-A1 NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS AstraZeneca AB (SE) 2007-10-03 EP claimed
WO-2006073366-A1 NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2006-07-13 WO claimed
US-20060099343-A1 Method of copper deposition from a supercritical fluid solution containing copper (I) complexes with monoanionic bidentate and neutral monodentate ligands E. I. DU PONT DE NEMOURS AND COMPANY 2006-05-11 US claimed
EP-1629902-A1 Method of copper deposition from a supercritical fluid solution containing copper (1) complexes with a neutral ligand E.I. DUPONT DE NEMOURS AND COMPANY (US) 2006-03-01 EP claimed
US-20250174409-A1 SOLID ELECTROLYTE CAPACITOR AND METHOD FOR MANUFACTURING SAME CARLIT CO., LTD. (JP) 2025-05-29 US disclosed
WO-2025052748-A1 METHOD FOR PRODUCING SOLID ELECTROLYTIC CAPACITOR 株式会社カーリット 2025-03-13 WO disclosed
CN-118843914-A Solid electrolytic capacitor and method for manufacturing the same 佳里多股份公司 2024-10-25 CN disclosed
US-6376665-B1 ANTIARTHRITIC AGENTS, ANTIINFLAMMATORY AGENTS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-04-23 US disclosed
EP-0474037-B1 Process for the production of 3-methylpyrazole BASF AG (DE) 1994-07-13 EP disclosed
US-5128480-A Reacting butenediols, ethynylalkylcarbinols or their acylates in sulfuric acid with a hydrazine compound using iodine or an iodine compound catalyst BASF AKTIENGESELLSCHAFT (DE) 1992-07-07 US disclosed
EP-0474037-A1 Process for the production of 3-methylpyrazole BASF Aktiengesellschaft (DE) 1992-03-11 EP disclosed